Subscribe
Earnings
4 min read

Purina's Cat Portfolio Is Carrying Nestle's Pet Care Growth, Again

Nestle's PetCare division grew 2.7 percent organically in H1 2026, trailing the group average, as premium cat food carried performance while dog lagged and margins slipped 30 basis points. It's a signal the pandemic-era pet food growth engine is normalizing into a tougher, share-driven fight.

Written by
The Underbite
Published on
July 24, 2026
Purina's Cat Portfolio Is Carrying Nestle's Pet Care Growth, Again

Nestle's PetCare division posted 2.7 percent organic sales growth in the first half of 2026, reaching 8.933 billion Swiss francs, with premium wet cat food and e-commerce doing most of the lifting while margins slipped slightly. It's a smaller deceleration than a dramatic headline number, but for a category that's been one of Nestle's most reliable growth engines for years, even modest softening alongside margin compression is worth an operator's attention.

PetCare grew slower than the group average, and margins gave up ground

Nestle's group-wide first-half 2026 sales came in at 43.109 billion Swiss francs, with organic growth of 3.6 percent and real internal growth of 1.5 percent. PetCare, the segment that houses Purina, grew slower than that group average: 8.933 billion Swiss francs in sales, organic growth of 2.7 percent, real internal growth of 1.8 percent, and a pricing contribution of just 0.9 percent. Underlying trading operating profit margin for the segment came in at 21.8 percent, down 30 basis points year over year. The second quarter alone showed organic growth of 2.8 percent, real internal growth of 2.0 percent, and pricing of 0.8 percent. Nestle's commentary pointed to continued strength in cat, with dog improving in the second quarter, and credited brands including Pro Plan, Purina ONE and Felix, particularly premium wet cat products and robust e-commerce performance across regions. Chief executive Philipp Navratil said the company's real-internal-growth-led strategy is delivering across the group, citing overall second-quarter organic growth of 3.7 percent and real internal growth of 1.8 percent, figures that describe Nestle as a whole rather than PetCare specifically.

Cat strength is masking a slower story in dog, and pricing power is fading

Growth trailing the group average is the detail worth sitting with. PetCare used to be Nestle's standout division, posting the kind of growth other categories envied during the pandemic-era pet ownership boom. That growth has been normalizing for a while as the industry-wide surge in pet acquisition cools and consumers pull back on discretionary premium spend, and this quarter's numbers are another data point in that trend rather than a new one. More telling is the split between real internal growth and pricing: 1.8 percent versus 0.9 percent means the growth Purina is generating now comes mostly from volume and mix, not from price increases. That's a meaningful shift from 2022 through 2024, when pricing power did much of the work offsetting input cost inflation across the pet food industry. Having largely exhausted that lever, Purina now has to compete more on volume, which is harder to win and shows up directly in the 30 basis point margin decline. Cat's outperformance relative to dog tracks a broader pattern showing up across the industry: smaller households and continued urbanization have made cat ownership the faster-growing side of pet acquisition in several developed markets, while dog categories face more competition from fresh and direct-to-consumer entrants along with growing private label share at retail. For competitors, whether other pet food majors or independent premium brands, the read isn't that Purina is weak. It's that the category's biggest player is now fighting for share in a maturing market rather than riding a rising tide, which tends to bring sharper promotional activity and tighter category segmentation industry-wide.

Nestle's own investor commentary leaned on the phrase "RIG-led growth strategy" to describe the quarter, which is a tell in itself. A volume-led growth story generally reflects a deliberate strategic choice to defend and grow share when pricing has stopped doing the work, and PetCare rarely gets flagged as a segment needing that kind of defense. It's a shift worth registering for any brand competing with Purina at retail, since a Purina fighting on volume typically means more promotional intensity, more retail media spend, and tighter shelf competition than a Purina simply raising prices and collecting the difference. Independent and premium challenger brands that have spent the past few years positioning against Purina's pricing should expect that gap to compress as Purina increasingly optimizes for volume growth rather than price realization.

The next checkpoint is whether dog momentum holds through the back half

The next checkpoint is whether the improving dog trend Nestle flagged for the second quarter holds through the back half of the year, or whether it was a single-quarter blip. Watch for margin trajectory in the next report given that pricing power has faded, and watch how competitors respond as Purina leans more on volume and e-commerce growth than on price. Nestle's next quarterly update will be the clearest test of whether PetCare's deceleration is a brief plateau or the start of a longer normalization for the category's largest player.

Source: Nestle Half-Year Results 2026

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
Vetspire Splits From Thrive, Lands a Battery Ventures Backing
Funding & M&A
4 min read

Vetspire Splits From Thrive, Lands a Battery Ventures Backing

Vetspire has spun out of Thrive Pet Healthcare's orbit with a growth investment from Battery Ventures and a new CEO, Zachary Seely. The AI-powered practice management platform, used by more than 800 veterinary hospitals and clinics, will operate independently while Thrive remains a customer. The deal tests whether AI-native vet software can draw institutional capital without a strategic parent underwriting it.

Read article
Read article
PetMeds Revenue Falls 20% as Takeover Fight Drags On
Earnings
6 min read

PetMeds Revenue Falls 20% as Takeover Fight Drags On

PetMeds' first-quarter revenue fell 19.9% to $41.0 million and cash reserves dropped to $13.1 million, even as the company narrowed its net loss to $6.1 million from $34.2 million a year earlier. The results land as an unsolicited $3-a-share buyout offer from SilverCape Investments remains on the table and a $37 million sale-leaseback of its headquarters awaits closing.

Read article
Read article
FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North
Regulatory
4 min read

FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North

The FDA granted Zoetis an emergency use authorization for Simparica Trio to treat New World screwworm in dogs, the first product cleared specifically for the threat. Texas has already begun requiring treatment before dogs cross certain lines, putting boarding facilities, transporters, and border-state vet practices under a new compliance mandate.

Read article
View all articles